August 18, 2021
Now Performing PD-L1 (22C3) through FDA Approved Therapy Keytruda
MLabs now offers new approved therapy with KEYTRUDA through the PD-L1 (22C3 Assay). KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. This FDA approved companion diagnostic for KEYTRUDA to evaluate triple-negative breast cancer patients.